Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Updated financial calendar

Thu, Apr 11, 2019 10:00 CET

Stockholm - April 11, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August. The dates for future reports and the AGM are shown below. Oncopeptides will also host a webcast on the same day as the interim reports are published.· The annual report for 2018 will be published between 23-26 April. · The interim report for Q1 2019 will be published on 21 May at 08.00 (CET). · The Annual General Meeting for 2018 will be held on 21 May and will start at 14.00 (CET). · The

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Updated financial calendar

Subscribe

Media